产品名称
硝基还原酶 来源于大肠杆菌, ≥90% (SDS-PAGE), recombinant, expressed in E. coli
recombinant
expressed in E. coli
assay
≥90% (SDS-PAGE)
form
lyophilized powder
specific activity
≥100 units/mL
mol wt
monomer 24000
greener alternative product characteristics
Waste Prevention
Safer Solvents and Auxiliaries
Design for Energy Efficiency
Learn more about the Principles of Green Chemistry.
sustainability
Greener Alternative Product
UniProt accession no.
greener alternative category
shipped in
wet ice
storage temp.
−20°C
Quality Level
Gene Information
Escherichia coli K12 ... nfsB(945483)
相关类别
Biochem/physiol Actions
硝基还原酶在NADPH或NADH为还原剂的氧还系统中有重要作用。
硝基还原酶(NTR)可催化还原硝基芳香族底物和醌。NTR的F124K突变体可用于癌症治疗，改善药物CB1954的敏化作用。
硝基还原酶增强了生命体对于含氮药物，比如甲硝唑的敏感度，它将氮基团转化为有毒的氮自由基。
能够还原奎宁。 该酶可以激活抗体引导酶前药治疗的前药。
Application
大肠杆菌来源硝基还原酶可结合猪肝酯酶(PLE)用于偶联结合反应。它还还可结合探针HyCL-3和HyCL-4-AM针对大鼠肝微粒体进行化学发光响应研究。
General description
含有PBS的冻干粉。 作为辅药不含有BSA
硝基还原酶是一种黄素蛋白，由NfsB基因编码。它包含一个二聚体，每个亚基具有217个氨基酸和活性位点。该结构具有FMN和与酶结合的底物。
Other Notes
在pH7.4、37℃、存在甲萘醌和NADH的条件下，一单位酶每分钟能够还原1μmole细胞色素C。
Preparation Note
使用没有动物组分的材料生产。
存储类别
13 - Non Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
法规信息
常规特殊物品
此项目有
Xin Feng et al.
Journal of nanobiotechnology, 20(1), 142-142 (2022-03-20)
Hypoxia is a distinguished hallmark of the tumor microenvironment. Hypoxic signaling affects multiple gene expressions, resulting in tumor invasion and metastasis. Quantification of hypoxic status although challenging, can be useful for monitoring tumor development and aggressiveness. However, hypoxia-independent factors such
Katherine R Ona et al.
Journal of bacteriology, 191(15), 4959-4965 (2009-05-26)
Nitrofurazone is reduced by cellular nitroreductases to form N(2)-deoxyguanine (N(2)-dG) adducts that are associated with mutagenesis and lethality. Much attention recently has been given to the role that the highly conserved polymerase IV (Pol IV) family of polymerases plays in
Mansooreh Jaberipour et al.
Biochemical pharmacology, 79(2), 102-111 (2009-08-12)
Prodrug activation gene therapy for cancer involves expressing prodrug-activating enzymes in tumour cells, so they can be selectively killed by systemically administered prodrug. For example, Escherichia colinfsB nitroreductase (E.C. 1.6.99.7)(NTR), sensitises cells to the prodrug CB1954 (5-[aziridin-1-yl]-2,4-dinitrobenzamide), which it converts
Bharat Bhushan et al.
Biochemical and biophysical research communications, 322(1), 271-276 (2004-08-18)
Previously, we reported that a salicylate 1-monooxygenase from Pseudomonas sp. ATCC 29352 biotransformed CL-20 (2,4,6,8,10,12-hexanitro-2,4,6,8,10,12-hexaaza-isowurtzitane) (C(6)H(6)N(12)O(12)) and produced a key metabolite with mol. wt. 346 Da corresponding to an empirical formula of C(6)H(6)N(10)O(8) which spontaneously decomposed in aqueous medium to
M J Lemmon et al.
Gene therapy, 4(8), 791-796 (1997-08-01)
A fundamental obstacle in gene therapy for cancer treatment is the specific delivery of an anticancer gene product to a solid tumor. Although several strategies exist to control gene expression once a vector is directly introduced into a tumor, as
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持